Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 28, 2025
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
GlobeNewswire
·
March 28, 2025
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabant SAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding …
Impulse Dynamics Receives European CE Mark For Expanded Indication For Diastolic Heart Failure
GlobeNewswire
·
March 28, 2025
Marlton, NJ, March 28, 2025 (GLOBE NEWSWIRE) -- Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to announce that it received European CE Mark approval for an expanded …
Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results
GlobeNewswire
·
March 28, 2025
FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the …
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks
GlobeNewswire
·
March 28, 2025
Regional Medical Leaders Embrace Daxor’s ezBVA Lab Service Oak Ridge, TN, March 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement technology, today announces a significant expansion into …
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
GlobeNewswire
·
March 28, 2025
THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development …
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire
·
March 28, 2025
Focused on the evaluation of strategic alternatives Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266 Phase 1 enrollment in …
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 28, 2025
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Commenced market launch and first commercial sales of Symvess - - Budget Impact Model for …
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
GlobeNewswire
·
March 28, 2025
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - …
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS
GlobeNewswire
·
March 28, 2025
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or …
Bio-Path Holdings Reports Full Year 2024 Financial Results
GlobeNewswire
·
March 28, 2025
HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs …
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
GlobeNewswire
·
March 28, 2025
- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High- …
FDA Issues Complete Response Letter for Etripamil for PSVT
GlobeNewswire
·
March 28, 2025
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. ( …
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
GlobeNewswire
·
March 28, 2025
FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancer Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected by mid-2025 SAN …
60 Degrees Pharmaceuticals Announces 2024 Annual Results
GlobeNewswire
·
March 28, 2025
FY 2024 net product revenues increased 140% to $607.6 thousand. FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand. WASHINGTON, March 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ( …
Winstrol Steroid: Benefits, Side Effects, Results & Buy Winstrol Pills Alternatives From CrazyBulk
GlobeNewswire
·
March 28, 2025
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- There exist numerous approaches to enhance muscle growth, a tantalizing prospect for many. However, achieving substantial muscle gains is far from instantaneous. Merely engaging in physical activities won't …
Ligandrol (LGD-4033) SARMs: Benefits, Results & Buy Ligandrol Pills Alternatives From CrazyBulk
GlobeNewswire
·
March 28, 2025
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- A significant portion of the populace leads lifestyles that compromise both cognitive and physical functionality. Prioritizing a healthy lifestyle is paramount for optimal brain and body performance, fostering a …
ProvaDent Reviews (Is It Safe And Legit?) Investigative Report On Ingredients, Side Effects, And Benefits!
GlobeNewswire
·
March 28, 2025
TALLMADGE, Ohio, March 28, 2025 (GLOBE NEWSWIRE) -- ProvaDent is precisely fabricated to support oral health by promoting a balanced oral microbiome. It works to encourage the growth of beneficial bacteria while reducing harmful ones. Maintaining this …
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
GlobeNewswire
·
March 28, 2025
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved …
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
GlobeNewswire
·
March 28, 2025
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first …
Communiqué de presse : Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO
GlobeNewswire
·
March 28, 2025
Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO Cette approbation fait suite à celle obtenue récemment dans l’Union européenne, en Chine et aux États-Unis et repose sur les résultats pivots de phase III …